Latest news with #AnixaBiosciences
Yahoo
14 hours ago
- Business
- Yahoo
Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
Fourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to Date SAN JOSE, Calif., Aug. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient in the fourth dose cohort has been treated in the ongoing Phase 1 clinical trial evaluating the Company's novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt"). Patients in the fourth cohort are receiving a dose of three million CAR-positive cells per kilogram of body weight—representing a 30-fold increase over the initial dose level. To date, no dose-limiting toxicities (DLTs) have been observed in the fourth cohort. Anixa's proprietary CAR-T program targets the follicle-stimulating hormone receptor (FSHR), which preclinical research indicates is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells—but not in healthy tissue. The ongoing first-in-human clinical trial (NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior lines of therapy. The Phase 1 study is designed to evaluate safety, determine the maximum tolerated dose, and monitor initial signals of clinical activity. "Our therapy continues to demonstrate a favorable safety profile, even at significantly higher cell doses," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "While this study is primarily designed to assess safety, we remain encouraged by early indications of potential efficacy as the trial progresses." Anixa's CAR-T technology was invented by Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine. The ongoing clinical trial is being conducted at Moffitt under the direction of Dr. Robert Wenham, Chair of the Gynecologic Oncology Program. Anixa holds an exclusive worldwide license to the FSHR-targeting CAR-T technology from The Wistar Institute. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on LinkedIn, X, Facebook and YouTube. Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:Mike CatelaniPresident, COO & CFOmcatelani@ View original content to download multimedia: SOURCE Anixa Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Independent
10-07-2025
- Health
- The Independent
Breakthrough breast cancer vaccine raises hopes of eradicating disease
A breakthrough breast cancer vaccine has completed Phase one trials, with over 75 percent of participants showing a strong immune response, raising hopes it could help eradicate the disease by 2030. The vaccine, developed by Anixa Biosciences and the Cleveland Clinic, targets alpha‑lactalbumin, a milk protein linked to aggressive triple-negative breast cancer, to help prevent and treat the disease. That form of cancer is known as the most deadly. During the first phase of the trial, 35 women, many with triple-negative breast cancer or a genetic risk, received the vaccine. Blood tests showed that more than 75 percent developed a strong immune response, indicated by antibodies on their white blood cells. That improved response can help a person's immune system identify and destroy cancerous cells. Side effects of the vaccine were limited to mild injection‑site irritation. Dr. Amit Kumar, Anixa's CEO, called the findings 'very exciting' in an interview with the New York Post . Developed by Anixa Biosciences and the Cleveland Clinic, the vaccine targets alpha-lactalbumin, a milk protein associated with aggressive triple-negative breast cancer, to aid in preventing and treating the disease. (Alamy/PA) 'It's a very new mechanism and we think that if this works and is able to prevent cancer, then we can perhaps eliminate breast cancer as a disease, just like we've done for polio and various other infectious diseases,' Kumar told the outlet. Phase two is scheduled for next year and will test a larger group of participants and expand testing to additional types of breast cancer. Unlike vaccines for infections, cancer vaccines face challenges because cancer originates from the body's own cells, making it harder for the immune system to distinguish them. Past attempts often targeted proteins found in both cancerous and healthy tissues, sometimes causing harmful immune responses. Experts are hopeful that the vaccine's success in early trials could lead to an eradication of the disease within a decade (AFP via Getty Images) Breast cancer cells often contain alpha-lactalbumin, a protein normally only present during pregnancy and breastfeeding. A Cleveland Clinic scientist proposed targeting it in women not planning to have more children 20 years ago, leading to the current vaccine trial. The US Department of Defense funded the study, but future progress may be affected by budget cuts. Researchers plan to present their results to the agency this year.
The Independent
09-07-2025
- Health
- The Independent
Breast cancer vaccine breakthrough raises hopes of eradicating disease
A breakthrough breast cancer vaccine has completed Phase one trials, with over 75 percent of participants showing a strong immune response, raising hopes it could help eradicate the disease by 2030. The vaccine, developed by Anixa Biosciences and the Cleveland Clinic, targets alpha‑lactalbumin, a milk protein linked to aggressive triple-negative breast cancer, to help prevent and treat the disease. That form of cancer is known as the most deadly. During the first phase of the trial, 35 women, many with triple-negative breast cancer or a genetic risk, received the vaccine. Blood tests showed that more than 75 percent developed a strong immune response, indicated by antibodies on their white blood cells. That improved response can help a person's immune system identify and destroy cancerous cells. Side effects of the vaccine were limited to mild injection‑site irritation. Dr. Amit Kumar, Anixa's CEO, called the findings 'very exciting' in an interview with the New York Post. 'It's a very new mechanism and we think that if this works and is able to prevent cancer, then we can perhaps eliminate breast cancer as a disease, just like we've done for polio and various other infectious diseases,' Kumar told the outlet. Phase two is scheduled for next year and will test a larger group of participants and expand testing to additional types of breast cancer. Unlike vaccines for infections, cancer vaccines face challenges because cancer originates from the body's own cells, making it harder for the immune system to distinguish them. Past attempts often targeted proteins found in both cancerous and healthy tissues, sometimes causing harmful immune responses. Breast cancer cells often contain alpha-lactalbumin, a protein normally only present during pregnancy and breastfeeding. A Cleveland Clinic scientist proposed targeting it in women not planning to have more children 20 years ago, leading to the current vaccine trial. The US Department of Defense funded the study, but future progress may be affected by budget cuts. Researchers plan to present their results to the agency this year.
Yahoo
08-07-2025
- Health
- Yahoo
Breast cancer vaccine breakthrough as more than 75% of women show immune response in new test
A breakthrough breast cancer vaccine has completed Phase one trials, with over 75 percent of participants showing a strong immune response, raising hopes it could help eradicate the disease by 2030. The vaccine, developed by Anixa Biosciences and the Cleveland Clinic, targets alpha‑lactalbumin, a milk protein linked to aggressive triple-negative breast cancer, to help prevent and treat the disease. That form of cancer is known as the most deadly. During the first phase of the trial, 35 women, many with triple-negative breast cancer or a genetic risk, received the vaccine. Blood tests showed that more than 75 percent developed a strong immune response, indicated by antibodies on their white blood cells. That improved response can help a person's immune system identify and destroy cancerous cells. Side effects of the vaccine were limited to mild injection‑site irritation. Dr. Amit Kumar, Anixa's CEO, called the findings 'very exciting' in an interview with the New York Post. 'It's a very new mechanism and we think that if this works and is able to prevent cancer, then we can perhaps eliminate breast cancer as a disease, just like we've done for polio and various other infectious diseases,' Kumar told the outlet. Phase two is scheduled for next year and will test a larger group of participants and expand testing to additional types of breast cancer. Unlike vaccines for infections, cancer vaccines face challenges because cancer originates from the body's own cells, making it harder for the immune system to distinguish them. Past attempts often targeted proteins found in both cancerous and healthy tissues, sometimes causing harmful immune responses. Breast cancer cells often contain alpha-lactalbumin, a protein normally only present during pregnancy and breastfeeding. A Cleveland Clinic scientist proposed targeting it in women not planning to have more children 20 years ago, leading to the current vaccine trial. The US Department of Defense funded the study, but future progress may be affected by budget cuts. Researchers plan to present their results to the agency this year.
The Independent
08-07-2025
- Health
- The Independent
Breast cancer breakthrough raises hopes for disease eradication
A breast cancer vaccine has completed phase one trials, showing a strong immune response in over 75 per cent of participants. Developed by Anixa Biosciences and the Cleveland Clinic, the vaccine targets alpha-lactalbumin, a protein linked to aggressive triple-negative breast cancer, aiming to prevent and treat the disease. The trial involved 35 women, many with triple-negative breast cancer or genetic risk, with blood tests confirming a strong antibody response and only mild injection-site irritation. Researchers are hopeful the vaccine could help eradicate breast cancer by 2030, with Anixa's CEO, Dr Amit Kumar, calling the findings 'very exciting'. Phase two trials are scheduled for next year to test a larger group and additional breast cancer types, with the study funded by the US Department of Defence. Breast cancer vaccine breakthrough as more than 75% of women show immune response in new test
